PROCEPT BioRobotics Corporation Announces Additional Positive Coverage Policies Regarding Aquablation Therapy for Men with Enlarged Prostates
09 6월 2022 - 9:00PM
PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical
robotics company focused on advancing patient care by developing
transformative solutions in urology, today announced that five new
regional private insurance plans have issued positive coverage
policies of Aquablation therapy for the surgical treatment of
benign prostatic hyperplasia (BPH). Three Blue Cross Blue Shield
(“BCBS”) Association healthcare plans are included in the recent
coverage additions along with Medical Mutual and Presbyterian
Healthcare Services. In the aggregate, the five positive policies
will provide coverage for approximately 8.5 million members.
The coverage policies issued are detailed below:
- Highmark, Inc., the sixth largest BCBS plan, covers
approximately 4.5 million members across Pennsylvania, New York,
West Virginia, and Delaware and took effect on May 2, 2022
- BCBS of Minnesota, the largest private payer in Minnesota,
covers approximately 2.1 million members and took effect on May 2,
2022
- BCBS of North Dakota, the largest private payer in North
Dakota, covers approximately 285,000 members and took effect on May
2, 2022
- Medical Mutual covers approximately 1.1 million members in the
state of Ohio and took effect on March 24, 2022
- Presbyterian Healthcare Services, the second largest payer in
New Mexico, covers approximately 500,000 members and took effect on
March 23, 2022
These coverage policies are in addition to the positive coverage
policies issued by Aetna and Independence BCBS in April 2022.
“These positive coverage decisions, driven by the strong body of
clinical support, demonstrate the continued acceptance of
Aquablation therapy,” said Reza Zadno, President and CEO. “We are
pleased that an approximate 8.5 million additional covered lives
will now have access to Aquablation therapy, a treatment that
allows patients to prioritize both safety and efficacy.”
About PROCEPT BioRobotics CorporationPROCEPT is
a surgical robotics company focused on advancing patient care by
developing transformative solutions in urology. PROCEPT develops,
manufactures and sells the AquaBeam Robotic System, an advanced,
image-guided, surgical robotic system for use in minimally invasive
urologic surgery with an initial focus on treating benign prostatic
hyperplasia, or BPH. BPH is the most common prostate disease and
impacts approximately 40 million men in the United States. PROCEPT
designed Aquablation therapy to deliver effective, safe and durable
outcomes for males suffering from lower urinary tract symptoms, or
LUTS, due to BPH that are independent of prostate size and shape or
surgeon experience. PROCEPT has developed a significant and growing
body of clinical evidence, which includes nine clinical studies and
over 100 peer-reviewed publications, supporting the benefits and
clinical advantages of Aquablation therapy.
Forward Looking StatementsThis release contains
forward‐looking statements within the meaning of federal securities
laws, including with respect to the Company’s projected financial
performance for full year 2022, statements regarding the potential
utilities, values, benefits and advantages of Aquablation® therapy
performed using PROCEPT’s products, including AquaBeam® Robotic
System, which involve risks and uncertainties that could cause the
actual results to differ materially from the anticipated results
and expectations expressed in these forward-looking statements. You
are cautioned not to place undue reliance on these forward-looking
statements. Forward-looking statements are only predictions based
on our current expectations, estimates, and assumptions, valid only
as of the date they are made, and subject to risks and
uncertainties, some of which we are not currently aware.
Forward-looking statements may include statements regarding
reimbursement coverage, market opportunity and penetration, the
Company’s possible or assumed future results of operations,
commercial momentum, or overall business strategy, Forward‐looking
statements should not be read as a guarantee of future performance
or results and may not necessarily be accurate indications of the
times at, or by, which such performance or results will be
achieved. These forward‐looking statements are based on PROCEPT’s
current expectations and inherently involve significant risks and
uncertainties. Actual results and the timing of events could differ
materially from those anticipated in such forward‐looking
statements as a result of these risks and uncertainties. These
risks and uncertainties are described more fully in the section
titled “Risk Factors” in PROCEPT’s filings with the Securities and
Exchange Commission (the “SEC”), including PROCEPT’s annual report
on Form 10-K filed with the SEC on March 22, 2022, and as updated
in our Quarterly Report on Form 10-Q for the quarter ended March
31, 2022. PROCEPT does not undertake any obligation to update
forward‐looking statements and expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any
forward‐looking statements contained herein. These forward-looking
statements should not be relied upon as representing PROCEPT’s
views as of any date subsequent to the date of this press
release.
Important Safety Information
All surgical treatments have inherent and associated side
effects. For a list of potential side effects
visit https://aquablation.com/safety-information/
Investor Contact:Gilmartin GroupMatt Bacso,
CFAMatt.bacso@gilmartinir.com
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024